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Abstract 
Background: In genome-wide screening studies for de novo mutations underlying autism and 
intellectual disability, mutations in the ADNP gene are consistently reported amongst the most 
frequent. ADNP mutations have been identified in children with autism spectrum disorder co-morbid 
with intellectual disability, facial features and deficits in multiple organ systems. However, a 
comprehensive clinical description of the Helsmoortel-Van der Aa syndrome is lacking. 
Methods: We identified a worldwide cohort of 78 individuals with likely disruptive mutations in 
ADNP from January 2014 to October 2016 through systematic literature search, by contacting 
collaborators, and through direct interaction with parents. Clinicians filled in a structured 
questionnaire on genetic and clinical findings to enable genotype-phenotype correlations. Clinical 
photographs and specialist reports were gathered. Parents were interviewed to complement the written 
questionnaires. 
Results: We report on the detailed clinical characterization of a large cohort of individuals with an 
ADNP mutation and demonstrate a distinctive combination of clinical features, including mild to 
severe intellectual disability, autism, severe speech and motor delay and common facial 
characteristics. Brain abnormalities, behavioral problems, sleep disturbance, epilepsy, hypotonia, 
visual problems, congenital heart defects, gastrointestinal problems, short stature and hormonal 
deficiencies are common co-morbidities. Strikingly, individuals with the recurrent p.Tyr719* mutation 
were more severely affected. 
Conclusions: This overview defines the full clinical spectrum of individuals with ADNP mutations, a 
specific autism subtype. We show that individuals with mutations in ADNP have many overlapping 
clinical features, distinctive from other autism/ID syndromes. In addition, our data show preliminary 
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Introduction 
Autism Spectrum Disorder (ASD) is a condition defind by deficits in social interaction, 
communication and selected behaviors (1). Each aspect of the disorder may vary in 
presentation, range and severity, cumulating in a bro d clinical spectrum. The frequency of 
the disorder is under continuous debate, but may affect up to 1.5% of the population (2). 
Although a genetic contribution to its etiology has been firmly demonstrated (3), it took the 
introduction of trio-based whole exome sequencing (WES) to truly accelerate substantially the 
identification of ASD genes. In these studies, individuals are screened along with their 
parents, enabling the unbiased detection of de novo mutations in large ASD cohorts (4-6). 
These initiatives are complemented by targeted resequencing of larger cohorts (7). Studies in 
ASD cohorts co-morbid with intellectual disability (ID) collectively demonstrate an 
unprecedented genetic heterogeneity of ASD, with no si gle gene responsible for more than a 
fraction of the total population. Several of the idntified genes appear to cluster in a subset of 
cellular networks, including networks enriched for ch omatin remodeling and synaptic 
functioning (5, 8). Overlap between ASD genes and genes causative for other 
neurodevelopmental disorders, including ID and seizur s, is common (9, 10). 
Despite the high heterogeneity and observed molecular overlap, there is preliminary evidence 
for the existence of clinical ASD subtypes. For insta ce, mutations in the chromatin 
remodeler CHD8 cause an ASD/ID subtype with specific physical characteristics, such as 
macrocephaly and significant gastrointestinal problems (11, 12). In contrast, individuals with 
a mutation in DYRK1A, a gene duplicated in Down syndrome, have ASD/ID, microcephaly, 
intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic 
behavior, hypertonia and a distinctive facial gestalt (13). Yet, the clinical delineation of 
ASD/ID syndromes has lagged behind their respective molecular definition. Since possible 
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the basis of the clinical presentation, it is of primary importance to define autism subtypes 
correctly at the molecular level (14). 
ADNP was one of the most frequently mutated genes across multiple recent WES and targeted 
molecular inversion probe (MIPs) sequencing studies in ASD/ID cohorts (6, 7). The ADNP 
gene plays a role in embryonic development, especially during the time of neuronal tube 
closure and is involved in chromatin remodeling (15-18). Based on the first ten individuals 
identified with ADNP-related ASD/ID, ADNP mutations were estimated to explain 1-2/1000 
ASD/ID cases and some shared clinical features weresuggested (19). Since that time, a 
number of case reports have expanded the phenotype f th Helsmoortel-Van der Aa 
syndrome (OMIM 615873) (20-23). Here, we describe the clinical details of a cohort of 78 
individuals from 16 countries with a likely disruptive mutation in ADNP. We herewith define 
a novel subtype of ASD/ID and at the same time, present evidence for a significant genotype-
phenotype correlation. 
 
Methods and Materials 
Participants 
The study was performed at the University of Antwerp, Belgium. Individuals were identified 
through exome sequencing in our own center or gathered from genetic centers worldwide 
offering exome-wide or targeted genetic screening in a clinical or a research setting. 
Additional individuals were collected on the website http://humandiseasegenes.com/adnp/. A 
minority of the individuals were previously described in case reports as cited above (19-23). 
All individuals were enrolled between Jan 1, 2014 and Oct 1, 2016. Inclusion required a 
clinical geneticist-confirmed diagnosis of a nonsense or frameshift mutation in the ADNP 
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development, craniofacial features and behavior. Essentially all mutations were identified by 
next generation sequencing of individuals with autism and/or developmental delay often in 
combination with additional syndromic features. In part the ADNP mutations were identified 
in individuals in preassembled ID/autism cohorts that were subjected to trio based whole 
exome sequencing or targeted MIP sequencing as describ d in Helsmoortel et al. (19). The 
remainder of our cohort was assembled from the indiv duals in whom an ADNP mutation was 
diagnosed after genetic testing using either neurodevelopmental gene panels or trio based 
whole exome sequencing. After the identification of a causative ADNP mutation in an 
individual, their clinical geneticist asked for consent to be included in this study. In each case 
the mutation that was identified using next generation sequencing was independently verified 
using Sanger sequencing either in our own or in the referring laboratory. Individuals carrying 
a missense mutation in ADNP were excluded from this study. All gene annotations have been 
made according to NM_015339.2 (hg19). Approval for this study was obtained from the 
Ethics Committee of the Antwerp University Hospital. Pictures were only published if the 
parents provided written informed consent on behalf of their child. 
 
Procedures 
Collaborating physicians were asked to fill out an extensive questionnaire with clinical and 
molecular information about the individuals they had identified and assessed. We specifically 
asked for the results of the test the individuals hd been subjected to, including but not limited 
to IQ-test and ADOS test. Medical specialist reports and MRI data were collected and 
systematically re-evaluated in order to refine the int rpretation of the findings. In order to 
compare the data that were collected in various parts of the world, not in all cases using the 
same tests and terminology, we curated all incoming data and recontacted the collaborating 
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helped us contact clinicians and parents, in order to complete and verify the details of the 
clinical information. 
Statistical Analysis 
Associations between reported clinical features were systematically tested in a pair-wise 
analysis using one-way ANOVA, Pearson correlation and Fisher Exact tests, depending on 
the nature of the variables. A listing of all 170 variables included in our analysis is provided 
in Table S1. For one-way ANOVA, features for which only a single level was available, were 
excluded. If ANOVA resulted in significant results (p<0.05), post-hoc TukeyHSD testing was 
applied to identify significant differences in mean. For Fisher Exact tests, a minimal of two 
levels per tested category, and at least 10 records per tested condition were required. In case 
either category contains three or more levels, p-values were calculated using Monte-Carlo 
simulation using 10,000 replicates. Association betwe n demographic features, including 
gender and age and clinical features was analyzed similarly. Additionally, we evaluated the 
presence of genotype-phenotype correlations. First, the three most frequent mutations were 
analyzed separately: p.Tyr719* (17 individuals), p.Leu831Ilefs*82/p.Asn832Lysfs*81 (14 
individuals) and p.Arg730* (5 individuals). Subsequntly, mutations were grouped according 
to gene location: in the N-terminus (25 individuals), at the center of the gene (49 individuals) 
and in the C-terminus (4 individuals). Finally, we analyzed mutations per domain. For each 
analysis, prevalence or extent of all individual clini al features was compared between the 
selected sub-cohort and the remaining individuals. Multiple testing correction was performed 
via the false discovery rate (FDR) method (Qvalue add-on package in R, version 2.6.0 (25)). 
All calculations were carried out in the software package in R (version 3.3.1 (26)). Significant 
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Results 
We included 78 individuals with a disruptive mutation in ADNP, including 44 males and 34 
females (Figs. 1,2). The mean age of our cohort is eight years and two months, with a range of 
1-40 years. Individuals were from 44 clinics in 16 countries. Parental consanguinity was not 
reported and no siblings were diagnosed with a mutation in ADNP. Five individuals have non-
identical healthy twin siblings. We found 46 unique mutations on the DNA level, of which 25 
were nonsense and 21 frameshift (Supplemental Table S2). All but three mutations were 
located in the fifth and last exon of the ADNP gene and predicted to escape nonsense 
mediated decay. On the protein level, three mutations were present in five or more 
individuals, including the p.Tyr719* mutation. Sixty-eight mutations in our cohort were 
confirmed de novo, eight mutations were of unknown inheritance and two C-terminal 
mutations were inherited. 
Pre- and perinatal observations and congenital abnormalities 
Most children were born at term (mean gestational age 38.7 weeks, range 30-42 weeks). Mean 
maternal and paternal age at birth is 30 and 32 years, respectively. Intra-uterine growth 
retardation was not reported. Overall, birth weight, height and head circumference were 
within normal ranges (Supplemental Table S3, Supplemental Fig. S1-A-C). 
Six individuals (12.5%) were born with renal anomalies (narrow ureters, bilateral vesico-
ureteral reflux which was surgically repaired; Table 1). Reported hand and feet abnormalities 
were nonspecific, including fetal finger pads, clinodactyly, small fifth fingers, brachydactyly, 
single palmar crease, sandal gap, pes planus, long or broad halluces and syndactyly of the 2nd 
and 3rd toe. Twenty-five percent had nail abnormalities such as thin or small nails, or 
hypoplastic nails of the fifth digit. Some had widely spaced nipples, pectus excavatum, pectus 
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palate. Two of the children were born with metopic craniosynostosis, and one of them needed 
surgery. Six children had plagiocephaly, of whom three wore a cranial molding helmet. 
Failure to thrive in early childhood was noted in a umber of individuals. Some of them 
appeared to have severe cardiac problems, requiring open heart surgery. Thirty-eight percent 
had one or more congenital cardiac defects. These wr diverse: atrial septal defect, patent 
ductus arteriosus, patent foramen ovale, mitral valve prolapse, ventricular septal defect and 
other cardiovascular malformations such as a right aortic arch, dysplastic aortic valve, 
tetralogy of Fallot, ductus arteriosus aneurysm, quadricuspidal aortic valve, aortic ectasia and 
a mild pulmonary valve stenosis were found. (Fig. 3-A)  
Facial appearance 
Individuals shared similar facial features, including a prominent forehead with a high anterior 
hairline, a wide and depressed nasal bridge, and a short nose with full, upturned nasal tip (Fig. 
4, Supplemental Table S4). One third of the individuals had downslanted palpebral fissures 
and prominent eyelashes. Ear malformations were obsrved in nearly half of individuals. 
Abnormalities included small or dysplastic, low-set and posteriorly rotated ears. The philtrum 
was long in 39.3% of study cohort. Seventy percent of individuals had a thin upper lip, often 
combined with an everted lower lip and a pointed chin t at appears more pronounced at 
younger age (Fig. 5). One third have widely spaced te th.  
Growth and endocrine system 
Twenty-three percent of the individuals have short sta ure (height <-2SD, range 2-23 years 
old; Supplemental Table S3, Supplemental Fig. S1-E). Nine individuals had hormonal 
deficiencies (Table 1). Two of these had isolated growth hormone deficiency, four had 
hypothyroidism and three a combination of both hormonal deficiencies. One 29-year-old 
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three of ten individuals older than six for whom information was available; one boy and one 
girl had pubic hair growth at the age of seven and eight years, and one girl had menarche at 
eight years of age. 
Development and neurology  
Fifty-two percent of the individuals in this cohort present with severe intellectual disability at 
the age of assessment, 36% have a moderate disability nd 12% have a mild disability. 
Developmental delay is present in all individuals, with motor delay being one of the key 
features. The average age to sit up independently is 12.8 months (cohort range 6 to 60 months, 
normal range 4 to 9 months (27), Supplemental Fig. S2-A). Delayed age of walking 
independently (after 18 months of age (27), Supplemental Fig. S2-B) was observed in 86.8% 
of the children, with average age of 2 years and 5.5 months (cohort range 15 to 72 months).  
Interestingly, individuals with a p.Tyr719* mutation start walking at 3.5 years, significantly 
later than the 2 years and 2 months of the remainder of the cohort (p<0.0001, One Way 
Anova). Seventy-eight percent of the children had hypotonia, while hypertonia was present in 
three children. Standing unassisted for long periods of time or walking long distances is 
difficult for many of the children. The walking pattern can be abnormal, e.g., broad-based or 
tip-toe gait, foot slap. Six children learned walk with support between the ages of 5.5 and 8 
years, after many years of physiotherapy. A minority were not able to walk at the time of last 
evaluation. 
Another key feature is speech delay which presents in 98.6% of individuals. Mean age of first 
words was 30 months (cohort range 7 to 72 months, as opposed to a normal range of 12 to 18 
months, Supplemental Fig. S2-C). Nineteen percent have no language development at all. 
Apparent loss of acquired abilities has been reportd in 12 children for skills like speaking, 
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considerable delay in bladder training and many are still not toilet-trained when approaching 
puberty. 
Sixteen percent have seizures, including absence seizures, focal seizures with reduced 
awareness, epilepsy with Continuous Spike and Waves during Slow Wave Sleep (CSWS), or 
unclassified seizures. At least five children are reported with breath holding spells. Some of 
them were hospitalized for multiple cyanotic episodes causing an acute life-threatening event. 
Autistic features, behavior and sleep 
Ninety-three percent of the individuals present with autistic features (Fig. 3-B). Sixty-seven 
percent of them have been reported to have a clinica  d agnosis of ASD. They have a strong 
sensory interest illustrated by putting fingers or objects in their mouth, or being attracted to 
lights or water. Repetitive use of objects, hand an fi ger mannerisms, stereotyped 
movements like rocking back and forth or hand flapping are common. Some present with 
echolalia. Sixty-seven percent have also been diagnosed with sensory processing disorder. A 
high pain threshold is reported in 63.6% of individuals. Interestingly, all individuals with a 
p.Tyr719* mutation are included in this group (p=0.0003, Fisher Exact Test). 
Although parents report that 88% of the children are overall happy and friendly, behavioral 
problems are reported in 77.6% of them. Several present with obsessive compulsive behavior, 
mood disorder, a high anxiety level, temper tantrums, self-injurious and (verbally) aggressive 
behavior. Forty-four percent of the individuals arehyperactive or easily distracted. About one 
third of them have a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Several 
individuals take behavior-regulating medication like methylphenidate or atypical 
antipsychotics like risperidone or olanzapine to help control behavioral disturbances, 
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Sleep problems are present in 65.2%. Some of them ar  extremely anxious, with struggles 
falling asleep and frequent night-time awakenings. Some were treated with melatonin. Many 
individuals have a low daytime activity level or exc ssive daytime sleepiness; a minority have 
sleep apnea. 
Cerebral imaging 
In this cohort, MRI of the brain was performed in 75.6% of the individuals. Fifty-six percent 
of them appeared to have cerebral abnormalities, including atypical white matter lesions, 
delayed myelination, cortical dysplasia or atrophy, perinatal hypoxic ischemic 
encephalopathy, hydrocephalus, and hippocampal hypoplasticity (Fig. 3-C). 
MRI images of five individuals were studied in detail. The following abnormalities were seen 
in multiple individuals: underdevelopment of the frontal lobes with simplified gyral pattern of 
the cortex and occasional hypoplasia of the bulbus olfactorius and chiasma opticum; a thin 
and/or short, underdeveloped corpus callosum and inferior vermis hypoplasia; abnormal, 
often asymmetric opercularization of the Sylvian fissure with sometimes abnormal overlying 
cortex; dilatation of the lateral ventricles, mostly in the frontal areas and dilated perivascular 
spaces of Virchow-Robin in the cerebral white matter (Fig. 6). 
Gastrointestinal problems 
Eighty-three percent of the individuals have feeding or gastrointestinal problems, mainly 
gastro-esophageal reflux, frequent vomiting and constipation (Fig. 3-D). A few have 
excessive appetite. At the age of assessment, 20.9% of the individuals were overweight and 
7.5% were obese, according to standard WHO classification (28). Two individuals have 
Crohn’s disease, one of them with a positive familial h story. Oral movement problems, with 
implications for feeding and speech, are common (45.6%), and significantly more common in 
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Test). Problems drinking liquids or aspiration difficulties were frequent. Eight individuals 
were fed by gastrostomy tube (G-tube) in early childhood. The individuals suffering from 
gastrointestinal problems present more often with sleep disturbances (p= 0.0005, Fisher Exact 
Test). 
Visual problems 
Visual problems were present in 73.6% of the individuals, especially hypermetropia (40.3%) 
and strabismus (49.2%), but also myopia and astigmas  (Fig. 3-E). Many of them are 
prescribed glasses. Forty-one percent of the individuals have a diagnosis of cerebral visual 
impairment (CVI). Ophtalmologic defects are diverse: ectropion, coloboma, congenital 
cataracts, nystagmus. Some have an everted or notched eyelid, or mild ptosis, the latter 
particularly in individuals with mutations in the NLS and C-terminal of this domain 
(p=0.0004, Fisher Exact Test). 
Additional problems 
Musculoskeletal problems were common (Fig. 3-F). In addition to joint hypermobility, mild 
scoliosis was present in some individuals. Four had hip problems. Thirty-four percent of the 
males had unilateral or bilateral cryptorchidism; two had bilateral inguinal hernias. Fifty-one 
percent of the individuals have recurrent infections. Many of the children experienced chronic 
otitis media requiring ventilation tubes. Some of them (11.7%) were diagnosed with mild 
hearing loss in childhood. Two children have hearing aids for sensorineural hearing loss. Ear-
Nose-Throat problems, including narrow ear canals, l ryngomalacia and sleep apnea, were 
present in 32.1% of the individuals.  
Discussion 
Individuals with mutations in ADNP present with mild to severe intellectual disability, autistic 
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may be accompanied by a wide range of medical conditi s, including very frequent (>75%) 
gastrointestinal and feeding problems, hypotonia, and behavioral disturbances. Frequent co-
morbidities (50-75%) include visual problems, brain malformations, sleep disturbances, 
hand/foot and musculoskeletal abnormalities, and frequent infections. Common (25-50%) 
associated features include congenital heart disease, otorhinolaryngologic problems and 
urogenital defects. Up to 25% of individuals have hormonal deficiencies, short stature or 
seizures. The clinical symptoms of Helsmoortel-Van der Aa syndrome show partial overlap 
with other genetic syndromes that include developmental delay and ASD, as evidenced by 
genetic testing of our cohort for disorders like Angelman, Prader-Willi, Kleefstra, Smith-
Magenis or Rett syndromes prior to the diagnosis of an ADNP mutation. As we not have 
access to the full clinical data of all individuals in the screening cohorts from which our 
cohort was assembled, we cannot determine to what extent a possible ascertainment bias has 
influenced the clinical presentation of the syndrome.  
A striking element is the presence of mutational hot spots. The p.Tyr719*, 
p.Leu831Ilefs*82/p.Asn832Lysfs*81 and p.Arg730* mutation each occurred independently in 
at least five individuals. Interestingly, we found evidence for a genotype-phenotype 
correlation. We noticed for instance that individuals with a p.Tyr719* mutation walked later 
and have a higher pain threshold than the individuals with other mutations. Individuals with 
mutations in and C-terminal of the NLS domain more ft n had ptosis or oral movement 
problems than individuals with mutation elsewhere in the gene. Our findings encourage 
further investigations on larger study cohorts to unveil possible additional genotype-
phenotype correlations. We did not find any evidence for gender, IQ-level or age-specific 
correlations.  
Social media is increasingly used by parents to connect with each other and with scientists. 
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genetic and clinical information and the parent’s experiences providing us with important new 
insights into symptoms, daily struggles and challenges. While consensus has to grow what 
level of evidence is required to include parental observations of this type in a scientific 
publication, some of these hypotheses have been succe sfully tested in follow-up studies. As 
an example, the recently reported early teething in individuals with an ADNP mutation started 
as a parental observation (29). 
Through a careful and structured comparison of the clinical symptoms of 78 individuals with 
a mutation in the ADNP gene, we delineated the clinical presentation of this specific subtype 
of autism. Our synthesis is indispensable in the decision-making process for caretakers and 
relatives. Moreover, it will significantly improve the interpretation of the clinical relevance of 
novel rare variants in the gene. The main limitation of our study is the relative young age of 
our study cohort. Long-term follow-up studies are necessary to define the developmental path 
of individuals with a mutation in ADNP. While to date most cases have been found on a 
genotype-first basis, a specific combination of features like ID, ASD, speech and motor delay 
and additional problems may emerge to screening for ADNP mutations in cohorts including 
older individuals. Finally, this clinical delineation can be used to monitor effects of potential 
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Figure Legends 
Figure 1: Schematic illustration of ADNP and its functional domains.  
ADNP consists of 5 exons, and 14 domains, including 9 zinc fingers, NAP, an eIF4E 
interaction motif, a Nuclear Localization Signal (NLS), an ARKS motif, a DNA binding 
homeobox domain and a PxVxL motif (15, 17, 30). Zinc fi gers: AA 74-97, 107-129, 165-
188, 221-244, 447-469, 489-510, 512-535, 622-647, 662-686; NAP AA 354-361; eIF4E 
interaction motif AA 490-499; NLS AA 716-733; ARKS motif AA 765-768; DNA binding 
homeobox domain AA 754-814; PxVxL HP1 interaction motif AA 819-823. Black arrows 
indicate the location of the mutations in the reported individuals, highlighting the 3 most 
frequent mutations.  
Figure 2: Demographic data of the reported individuals.  
(A) Country of Origin, (B) Gender and (C) Age distrbution. 
Figure 3: Clinical features reported in individuals with ADNP mutation.  
(A) Cardiac abnormalities, (B) Behavioral problems, (C) Brain MRI abnormalities, (D) 
Feeding and Gastrointestinal problems, (E) Visual problems, (F) General health problems. 
Figure 4: Facial features of individuals with mutations in ADNP.  
Frontal and lateral views. Note the prominent forehead with high anterior hairline, the wide 
and depressed nasal bridge, and short nose with full, upturned nasal tip. Informed consent has 
been obtained for publication of all images present in this paper. (Individual numbers from 
Supplemental Table S2 corresponding to the pictures: A=49, B=34, C=44, D=21, E=17, 
F=63, G=28, H=29, I=45, J=11, K=38, L=15, M=48, N=50, O=60, P=36, Q=58, R=33, S=51, 
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Figure 5: Individuals at different ages showing evolution with age.  
(A) Individual 1 at age 10m, 15m, 29m, 4y, 6y;  
(B) Individual 32 at age 13m, 26m, 3y10m, 5y11m, 5y11m;  
(C) Individual 40 at age 4m, 13m, 13m, 3y6m, 3y6m;  
(D) Individual 65 at age 3m, 10m, 24m, 4y9m, 8y9m.  
Informed consent has been obtained for publication of all images present in this paper. 
Figure 6. Brain MRI of a child with a mutation in the ADNP gene. 
(A) Brain MRI of individual 49 performed at age 13 months showing generalized and frontal 
cortical atrophy and a gracile corpus callosum. (sagittal, T2 weighted FLAIR)  
(B) Brain MRI of individual 49 performed at age 19 months showing frontotemporal atrophy. 
(axial, T1-weighted) 
(C) Brain MRI of individual 45 performed at age 12 years showing mild frontal atrophy. 
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Figures 
Figure 1. Schematic illustration of ADNP and its functional domains.  
ADNP consists of 5 exons, and 14 domains, including 9 zinc fingers, NAP, an eIF4E 
interaction motif, a Nuclear Localization Signal (NLS), an ARKS motif, a DNA binding 
homeobox domain and a PxVxL motif (15, 17, 30). Zinc fingers: AA 74-97, 107-129, 165-
188, 221-244, 447-469, 489-510, 512-535, 622-647, 662-686; NAP AA 354-361; eIF4E 
interaction motif AA 490-499; NLS AA 716-733; ARKS motif AA 765-768; DNA binding 
homeobox domain AA 754-814; PxVxL HP1 interaction motif AA 819-823. Black arrows 
indicate the location of the mutations in the reported individuals, highlighting the 3 most 
frequent mutations.  
 
Figure 2. Demographic data of the reported individuals.  
(A) Country of Origin, (B) Gender and (C) Age distrbution. 
 
Figure 3. Clinical features reported in individuals with ADNP mutation.  
(A) Cardiac abnormalities, (B) Behavioral problems, (C) Brain MRI abnormalities, (D) 
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Figure 4. Facial features of individuals with mutations in ADNP. 
Frontal and lateral views. Note the prominent forehead with high anterior hairline, the wide 
and depressed nasal bridge, and short nose with full, upturned nasal tip. Informed consent has 
been obtained for publication of all images present in this paper. (Individual pictures 
correspond to the numbers in Supplemental Table S2 as follows: A=49, B=34, C=44, D=21, 
E=17, F=63, G=28, H=29, I=45, J=11, K=38, L=15, M=48, N=50, O=60, P=36, Q=58, R=33, 
S=51, T=39, U=42, V=31, W=41, X=10, Y=70, Z=27). 
Figure 5. Individuals at different ages showing evolution with age 
(A) Individual 1 at age 10m, 15m, 29m, 4y, 6y;  
(B) Individual 32 at age 13m, 26m, 3y10m, 5y11m, 5y11m;  
(C) Individual 40 at age 4m, 13m, 13m, 3y6m, 3y6m;  
(D) Individual 65 at age 3m, 10m, 24m, 4y9m, 8y9m.  
Informed consent has been obtained for publication of all images present in this paper. 
 
Figure 6. Brain MRI of a child with a mutation in the ADNP gene 
 
(A) Brain MRI of individual 49 performed at age 13 months showing generalized and frontal cortical atrophy 
and a gracile corpus callosum. (sagittal, T2 weightd FLAIR)  
(B) Brain MRI of individual 49 performed at age 19 months showing frontotemporal atrophy. (axial, T1-
weighted) 



















Table 1. Clinical features of the reported individuals with mutation in the ADNP gene. 
General information   
Age at examination (range) 1-40y (mean 8y 2m) 78/78 
Gender F:M 34:44 78/78 
Gestational age (weeks) 38.7 70/70 
Age father at time of birth 32.1y 65/65 
Age mother at time of birth 29.8y 67/67 
Mutation information   
De novo ADNP mutation 97.1% 68/70 
Nonsense mutation 56.4% 44/78 
Frameshift mutation 43.6% 34/78 
Growth   
Short stature (< -2SD) 23.2% 16/69 
Neurodevelopmental features   
Developmental delay / Intellectual disability (ID) 100.0% 73/73 
Mild ID 12.3% 9/73 
Moderate ID 35.6% 26/73 
Severe ID 52.1% 38/73 
Motor delay 95.9% 71/74 
Sitting independently (mean age) 1.1y 58/58 
Walking independently 86.8% 66/76 
Walking independently (mean age) 2.5y 64/64 
Speech delay 98.6% 70/71 
First words (age) 2.5y 49/49 
















Autism Spectrum Disorder including autistic features 92.8% 64/69 
ADHD 43.9% 25/57 
Loss of skills 20.3% 12/59 
Bladder training delay 81.1% 43/53 
Feeding and gastrointestinal problems 83.3% 60/72 
Gastroesophageal Reflux (Disease) 58.5% 38/65 
Constipation 49.3% 34/69 
Oral movement problems 45.6% 26/57 
Lack of satiation 41.5% 22/53 
Problems swallowing liquids 32.2% 19/59 
Frequent vomiting 29.5% 18/61 
Aspiration difficulties 21.4% 12/56 
Gastrostomy tube (G-tube) 12.7% 8/63 
Obesity 7.5% 5/67 
Neurological problems and behavior   
Hypotonia 78.3% 54/69 
Hypertonia 3.8% 3/78 
Seizures 16.2% 12/74 
Cerebral imaging - structural brain abnormalities 55.9% 33/59 
Wide ventricles 29.4% 15/51 
Corpus Callosum Underdevelopment 18.4% 9/49 
Cerebral atrophy 17.8% 8/45 
Delayed myelination 8.9% 4/45 
White matter lesions 7.5% 4/53 
Cortical dysplasia 3.8% 2/52 
MRI brain abnormalities· unspecified 36.2% 17/46 
















Temper tantrums/aggression 83.3% 20/24 
Obsessive compulsive behavior 64.0% 16/25 
Mood disorder 56.3% 9/16 
Self-injurious behavior 20.0% 2/10 
Insensitivity to pain 63.6% 35/55 
Sensory Processing Disorder 66.7% 28/42 
Sleep problems 65.2% 45/69 
Visual system 73.6% 53/72 
Strabismus 49.2% 31/63 
Cerebral Visual Impairment (CVI) 41.2% 14/34 
Hypermetropia 40.3% 25/62 
Ptosis 24.2% 15/62 
Nystagmus 11.7% 9/77 
Myopia 7.9% 5/63 
Colobomata 5.6% 4/72 
Ear-Nose-Throat (ENT) system 32.1% 25/78 
Narrow hearing canal 87.5% 7/8 
Frequent otitis media 85.7% 12/14 
Hearing tubes 73.3% 11/15 
Hearing loss 11.7% 7/60 
Obstructive Sleep Apnea Syndrome (OSAS) 6.6% 5/76 
Cardiovascular system 37.7% 26/69 
Atrial Septal Defect 15.9% 11/69 
Patent Ductus Arteriosus 8.7% 6/69 
Mitral Valve Prolaps 5.8% 4/69 
Patent Foramen Ovale 5.8% 4/69 
















Tetralogy of Fallot 1.4% 1/69 
Cardiac defect· unspecified 8.7% 6/69 
Urogenital system 28.0% 21/75 
Cryptorchidism 34.3% 12/35 
Renal anomalies 12.5% 6/48 
Small genitalia 5.4% 4/74 
Endocrine system 24.5% 12/49 
Early puberty 30.0% 3/10 
Thyroid hormone problems 15.2% 7/46 
Growth hormone deficiency 10.9% 5/46 
Musculoskeletal system 54.9% 39/71 
Joint hypermobility 37.7% 23/61 
Scoliosis 17.2% 11/64 
Hip problems (hip dysplasia, Perthes' disease, dislocated hips) 7.5% 4/53 
Thorax abnormalities 22.2% 12/54 
Pectus excavatum 14.8% 8/54 
Pectus carinatum 5.6% 3/54 
Narrow thorax 1.9% 1/54 
Abnormal skull shape 13.9% 10/72 
Plagiocephaly 8.3% 6/72 
Trigonocephaly 2.8% 2/72 
Brachycephaly 4.2% 3/72 
Hand and foot abnormalities 62.3% 43/69 
Finger abnormalities (prominent distal phalanges, prominent interphalangeal 
joints, polydactyly, interdigital webbing, 2-3 toe syndactyly, 5th finger 
clinodactyly, small fifth finger or absent distal phalanx of fifth finger, tapering 

















Single palmar crease 10.8% 7/65 
Nail anomalies 25.0% 14/56 
Sandal gap 19.6% 11/56 
Toe abnormalities (broad halluces, 2-3 toe syndactyly, brachydactyly) 10.8% 7/65 
Other   
Early teeth 71.1% 32/45 
Frequent infections  50.7% 35/69 
Widely spaced nipples 20.4% 11/54 
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Clinical Presentation of a Complex Neurodevelopmental Disorder 





Table S1. Parameters used for statistical analyses  
Epidemiology 
Country of lab 
Country of Origin 
Gender 
Age (months) - last observation 
Age father (years) - at time of birth 
Age mother (years) - at time of birth 
Part of twin 
Growth 
At birth: duration gestation (weeks) 
   Weight, g  
   Weight, SD     
   Length, cm  
   Length, SD 
   OFC, cm 
   OFC, SD 
Post-natal - age last measurements (yr) 
   Weight, SD 
   Height, SD 
   OFC, SD 
BMI 
Short stature (< -2SD) 
Development 
Delay/ ID : severe; moderate; mild 
Motor delay 
   Sitting (months) 
   Walking independently 
   Walking independently from the age of (months) 
Speech delay 
   No speech (nonverbal child) 
   Speech - first words (months) 






















Obsessive compulsive behavior 
Social behavior 




   Feeding G-Tube 
   GERD or Reflux 
   Oral movement difficulties 
   Oral drinking liquid problems 
   Satiety problems: does not seem to "get full" 









Narrow hearing canal 
Hearing tubes 
Frequent otitis media 
Eye defects 
   Hypermetropia 
   Strabismus 
   Ptosis 
   Hypertelorism 
   CVI 
   Myopia 





Abnormal hair thickness 




Sagging periorbital skin 
Narrow palpebral fissures 
Upward slant palpebral fissures 
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Pointed chin 
Wide nasal bridge 
Narrow nasal bridge 
Low nasal bridge 
Upturned nasal tip (anteverted nares) 
Broad nasal tip 







Thin upper vermillion 
Thick lower vermillion 
Drooping lower lip 
Cleft palate / submucous cleft 
Widely spaced teeth 
Teeth problems 
Low set or posteriorly rotated ears 
Malformed ears 
Small ears 
Trunc and limbs 
Thick neck 
Scoliosis 











Fetal finger pads 
Brachydactyly 





















Van Dijck et al.  Supplement 
4 
Atrial Septal Defect 
Mitral Valve Prolapse 
Ventricular Septal Defect 
Patent Foramen Ovale at birth 
Patent Ductus Arteriosus at birth 
Tetralogy of Fallot 
Other cardiac defect 
Neuroradiology 
MRI brain abnormality 
   Delayed myelination 
   Wide ventricles 
   Callosal body underdevelopment 
   Cerebral atrophy 
   White matter lesions 
   Cortical dysplasia 
   Other MRI brain abnormalities 













Obstructive Sleep Apnea Syndrome 
Bladder training delay 
Hormonal deficiencies 
Insensitivity to pain 
Sensory Processing Disorder 
Growth hormone deficiency 
Thyroid hormone problems 
















Van Dijck et al.  Supplement 
5 
Table S2. List of mutations identified in the reported individuals (NM_015339.2 (hg19)) 
cDNA Protein gDNA CADD 
score* 
Patient ID Frequency 
c.1A>G  p.Met1? g.49520533T>C  24.6 48 1 
c.118C>T p.Gln40* g.49518637G>A 37 11 1 
c.190dupA p.Thr64Asnfs*35 g.49518565insT 34 64 1 
c.339delC p.Phe114Serfs*47 g.49510912delG 21.2 21 1 
c.372_373delGT  p.Ile125* g.49510878_49510879delAC 33 54 1 
c.484C>T p.Gln162* g.49510767G>A 36 47 1 
c.517C>T p.Arg173* g.49510734G>A 36 17 1 
c.539_542delTTAG p.Val180Glyfs*17 g.49510709_49510712delCTAA 34 28, 39 2 
c.646 C>T p.Arg216* g.49510605G>A 36 20 1 
c.651_655delAGAGA p.Glu218* g.49510596_49510600delTCTCT 29 68 1 
c.673C>T p.Arg225* g.49510578G>A 35 42, 66 2 
c.790C>T p.Arg264* g.49510461G>A 36 73 1 
c.819delC p.Lys274Asnfs*31 g.49510432delG 25.2 62 1 
c.1026_1027insT p.Val343Cysfs*56 g.49510224_49510225insA 33 23 1 
c.1033C>T p.Gln345* g.49510218G>A 37 65 1 
c.1046_1047delTG  p.Leu349Argfs*49 g.49510204_49510205delCA 32 13 1 
c.1102C>T  p.Gln368* g.49510149G>A 37 80 1 
c.1134T>G p.Tyr378* g.49510117A>C 23.5 50 1 
c.1184_1190delAGTCTGC  p.Gln395Leufs*11 g.49510061_49510067delGCAGACT 34 60 1 
c.1211C>A p.Ser404* g.49510040G>T 37 2 1 
c.1216delC p.Gln406Serfs*2 g.49510035delG 33 59 1 
c.1222_1223delAA p.Lys408Valfs*31 g.49510028_49510029delTT 32 3 1 
c.1235delT p.Leu412Profs*10 g.49510016delA 31 52 1 
c.1754dupA p.Asn585Lysfs*2 g.49509497dupT 26.5 75 1 
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cDNA Protein gDNA CADD 
score* 
Patient ID Frequency 
c.2089C>T p.Gln697* g.49509162G>A 39 36 1 
c.2129delC p.Pro710Glnfs*6 g.49509122del 35 41 1 
c.2129dupC p.Ser711Lysfs*24 g.49509122dupG 34 29 1 
c.2153_2165delCTTACGAGCAAAT p.Thr718Argfs*6 g.49509086_49509098delATTTGCTCGTAAG 35 4 1 
c.2156dup p.Tyr719* g.49509095dupT 
32 
5, 10, 27, 38, 44, 
55, 70, 79 
8 
c.2157C>A p.Tyr719* g.49509094G>T 22.9 57, 58, 63 3 
c.2157C>G p.Tyr719* g.49509094G>C 
21.9 
12, 16, 26, 34, 49, 
56, 
6 
c.2188C>T p.Arg730* g.49509063G>A 36 18, 25, 45, 69, 74 5 
c.2206dupA p.Ser736Lysfs*2 g.49509045dupT 28.4 51 1 
c.2213C>G p.Ser738* g.49509038G>C 43 71 1 
c.2251delGinsTAAA p.Val751* g.49509000delCinsTTTA 38 31 1 
c.2268_2269insT p.Lys757*  g.49508982_49508983insA 35 53 1 
c.2287delT p.Ser763Profs*9 g.49508964delA 35 46 1 
c.2310delT p.Leu771* g.49508941delA 32 33 1 
c.2491_2494delTTAA p.Leu831Ilefs*82 g.49508757_49508760delTTAA 35 6, 8, 15, 78 4 
c.2495_2499delATAAA p.Asn832Serfs*4 g.49508752_49508756delTTTAT 35 61 1 
c.2496_2499delTAAA p.Asn832Lysfs*81 g.49508752_49508755delTTTA 
35 
1, 14, 19, 24, 30, 
32, 35, 40, 67, 72 
10 
c.2808delC p.Tyr936* g.49508443delG 16.42 7 1 
c.3047dupA p.Ala1017Glyfs*6 g.49508204dupT 35 37 1 
c.3069_3072delAGAG p.Arg1023Serfs*3 g.49508179_49508182delCTCT 35 43 1 
c.3170T>A p.Leu1057* g.49508081A>T 47 22 1 













Van Dijck et al.  Supplement 
7 
Table S3. Growth in individuals with Helsmoortel-Van der Aa syndrome  
Growth 
  Mean Mean z-
score 
z-score < -2 (%) z-score > +2 (%) Number of patients 
  F M F M F M Total F M Total F M Total 
Birth weight (g) 2965.8 3155.5 -0.3 0.4 10.0% 6.1% 7.9% 0.0% 9.1% 4.8% 30 33 63 
Birth length (cm) 48.9 49.5 -0.2 0.3 12.5% 0.0% 6.3% 0.0% 0.0% 0.0% 24 24 48 
Birth OFC (cm) 34.7 34.5 0.5 0.1 12.5% 0.0% 6.5% 0.0% 0.0% 0.0% 16 15 31 
Weight at last observation NA NA 0.4 0.7 0.0% 5.9% 3.2% 10.3% 5.9% 7.9% 29 34 63 
Length at last observation NA NA -0.4 -0.8 22.6% 23.7% 23.2% 0.0% 2.6% 1.4% 31 38 69 
OFC at last observation NA NA -0.4 -0.3 10.7% 5.9% 8.1% 0.0% 0.0% 0.0% 28 34 62 
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Table S4. Facial features of the reported individuals with mutation in the ADNP gene 
Facial feature Frequency Total 
Thin upper vermillion 70.3% 45/64 
Prominent forehead 65.6% 42/64 
Wide nasal bridge 50.0% 33/66 
High hairline 50.0% 33/66 
Short nose 49.2% 31/63 
Malformed ears 48.5% 32/66 
Upturned nasal tip 46.7% 28/60 
Everted lower lip 45.5% 25/55 
Long philtrum 39.3% 22/56 
Thick lower vermillion 36.4% 20/55 
Downward slant palpebral fissures 33.3% 20/60 
Widely spaced teeth 34.6% 18/52 
Broad nasal base 29.6% 16/54 
Broad nasal tip 26.3% 15/57 
Teeth problems 24.5% 13/53 
Narrow palpebral fissures 24.1% 14/58 
Large mouth 23.2% 13/56 
Low nasal bridge 20.6% 13/63 
Eversion/notch eyelid 19.0% 12/63 
thick eyebrows 18.3% 11/60 
Coarse face 16.9% 11/65 
Prominent eyelashes 16.7% 10/60 
Broad philtrum 16.1% 9/56 
Low-set or posteriorly rotated ears 14.7% 10/68 
Abnormal hair thickness 14.0% 8/57 
Sagging periorbital skin 13.6% 8/59 
Small ears 11.6% 8/69 



















Figure S1. Growth in individuals with Helsmoortel-Van der Aa syndrome 
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Figure S2. Developmental milestones 
(A) Sitting independently. In orange: WHO reference cohort1. Grey area: Individuals with p.Tyr719* mutation; (B) Walking independently. In orange: WHO 
reference cohort1. Grey area: Individuals with p.Tyr719* mutation; (C) First words. Shaded area: Typically developing children.  
1 The WHO Child Growth Standards. 2017. http://www.who.int/childgrowth/.  
